Abstract
Current risk scores for predicting ischemic heart disease (IHD) risk—the leading cause of global mortality—have limited efficacy. While body composition (BC) imaging biomarkers derived from abdominopelvic computed tomography (CT) correlate with IHD risk, they are impractical to measure manually. Here, in a retrospective cohort of 8,197 contrast-enhanced abdominopelvic CT examinations undergoing up to 5 years of follow-up, we developed improved multimodal opportunistic risk assessment models for IHD by automatically extracting BC features from abdominal CT images and integrating these with features from each patient’s electronic medical record (EMR). Our predictive methods match and, in some cases, outperform clinical risk scores currently used in IHD risk assessment. We provide clinical interpretability of our model using a new method of determining tissue-level contributions from CT along with weightings of EMR features contributing to IHD risk. We conclude that such a multimodal approach, which automatically integrates BC biomarkers and EMR data can enhance IHD risk assessment and aid primary prevention efforts for IHD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was not supported by industry. J.M.Z.C. is supported by a graduate fellowship award from Knight-Hennessy Scholars at Stanford University, and receives research support from GE Healthcare not related to this work. A.S.C. has provided consulting services to Skope MR, Inc., Subtle Medical, Chondrometrics GmbH, Image Analysis Group, Edge Analytics, ICM Co., and Culvert Engineering; and is a shareholder of Subtle Medical, LVIS Corporation, and Brain Key; and is on the advisory board for Chondrometrics GmbH and Brain Key; and receives research support from GE Healthcare and Philips not related to this work. A.T.S. receives funding from the National Heart, Blood, and Lung Institute (K23 HL151672-01). F.R. was funded by a career development award from the National Heart, Lung, and Blood Institute (K01 HL 144607) and the American Heart Association/Robert Wood Johnson Harold Amos Medical Faculty Development Program. B.P. receives support from an institutional grant (General Electric) not related to this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Stanford University institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our model predictions and outcome labels will be made publicly available alongside our code. The raw data are not publicly available due to privacy information embedded directly within the data. Data are available on request due to privacy or other restrictions. The data that support the findings of this study are available on request from the corresponding author (B.P.).
